Balyasny Asset Management
CTKB icon

Balyasny Asset Management’s Cytek Biosciences CTKB Stock Holding History

Balyasny Asset Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,238
Closed -$90.6K – 2803
2024
Q2 		$90.6K Sell
16,238
-29,529
-65% -$177K ﹤0.01% 2407
2024
Q1 		$307K Buy
45,767
+16,840
+58% +$133K ﹤0.01% 2252
2023
Q4 		$264K Buy
28,927
+15,267
+112% +$96.1K ﹤0.01% 2218
2023
Q3 		$75.4K Sell
13,660
-68,304
-83% -$548K ﹤0.01% 2141
2023
Q2 		$700K Sell
81,964
-40,055
-33% -$359K ﹤0.01% 1752
2023
Q1 		$1.12M Sell
122,019
-994
-0.8% -$10.7K ﹤0.01% 1698
2022
Q4 		$1.26M Buy
+123,013
New +$1.65M ﹤0.01% 1582

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Balyasny Asset Management's CTKB Position: Q3 2024 in Review

Balyasny Asset Management sold out of Cytek Biosciences (CTKB) in Q3 2024, closing a stake of 16,238 shares — an estimated $90.6K sold.

Balyasny Asset Management first reported a position in CTKB in Q4 2022 and held it in 7 quarters. The position peaked at $1.26M in Q4 2022. 136 funds tracked by Wall St. Rank hold CTKB as of Q3 2024.

  • Balyasny Asset Management reported no remaining Cytek Biosciences position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 16,238 Cytek Biosciences shares in Q3 2024, an estimated $90.6K.
  • Balyasny Asset Management first reported a position in Cytek Biosciences in Q4 2022 and held it in 7 quarters.
  • Balyasny Asset Management's Cytek Biosciences position peaked at $1.26M in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.